ESMO 2024: Regeneron's melanoma combo therapy benefit continues beyond two years
Regeneron's melanoma combo therapy, fianlimab plus Libtayo, shows 25% complete response and 57% objective response rates after 23 months in a Phase I trial, with ongoing Phase III studies.
Related Clinical Trials
Reference News
ESMO 2024: Regeneron's melanoma combo therapy benefit continues beyond two years
Regeneron's melanoma combo therapy, fianlimab plus Libtayo, shows 25% complete response and 57% objective response rates after 23 months in a Phase I trial, with ongoing Phase III studies.